 Entera Bio Ltd. ENTX, a leader in the development of orally delivered large molecule therapeutics, announced its financial and operational results for the quarter and year ended December 31, 2019. Completed Phase 2 PKPD trial of EB612 in hypoparathyroidism and presented the results at the 2019 Annual Meeting of the American Society for Bone and Mineral Research: The trial, which evaluated the Pharmacokinetic PK and Pharmacodynamic PD profile of EB612, was conducted in 16 patients and followed Enteras prior clinical trials of oral human parathyroid hormone PTH. 